Free tool
Drug Trial Radar: Respiratory
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
11
Active, not recruiting, industry sponsors, Respiratory, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed646
11 trials
Showing 1 to 11, recently updated first.
- A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese VolunteersActive, not recruiting
AmgenAmgen (AMGN)
NCT07745907 · 28 participants (planned) · Start Aug 7, 2026 · Primary completion Mar 17, 2027
Drug: AMG 691 · For: Healthy Participants
Sites: Las Vegas, Nevada
- A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary DiseasePivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06154837 · 127 participants · Start Nov 27, 2023 · Primary completion Dec 16, 2026
Drug: GSK3862995B; Placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Yuma, Arizona; Hialeah, Florida; Orange City, Florida · 31 sites in all
- A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283Active, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT07712393 · 24 participants · Start Jul 17, 2026 · Primary completion Apr 13, 2027
Drug: GSK5784283 · For: Asthma
Sites: Austin, Texas
- A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate AsthmaActive, not recruiting
AmgenAmgen (AMGN)
NCT06637371 · 21 participants · Start Oct 16, 2024 · Primary completion Apr 10, 2027
Drug: AMG 691; Placebo · For: Asthma
Sites: Lake Forest, California; Aventura, Florida; Palmetto Bay, Florida · 21 sites in all
- A Phase 1 Relative Bioavailability Study of a VX-581 Tablet FormulationActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07813039 · 16 participants · Start Sep 23, 2026 · Primary completion Oct 27, 2026
Drug: VX-581 · For: Cystic Fibrosis
Sites: Tempe, Arizona
- Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation ImagingActive, not recruiting
Polarean, Inc.Industry
NCT06271408 · 6 participants (planned) · Start Mar 19, 2024 · Primary completion Dec 31, 2026
Drug: Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution · For: Chronic Obstructive Pulmonary Disease
Sites: Charlottesville, Virginia
Revagenix, Inc.Industry
NCT07709494 · 64 participants (planned) · Start Jul 13, 2026 · Primary completion Jul 2027
Drug: Placebo: Normal saline · For: Healthy Participants; Non-cystic Fibrosis Bronchiectasis
Sites: Miami, Florida
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With AsthmaActive, not recruiting
Apogee Therapeutics, Inc.Industry
NCT06920901 · 31 participants · Start Mar 27, 2025 · Primary completion Sep 17, 2026
Drug: APG777; Placebo · For: Asthma
Sites: La Jolla, California; Long Beach, California; San Jose, California · 11 sites in all
- Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)Active, not recruiting
Thirty Respiratory LimitedIndustry
NCT06663176 · 60 participants (planned) · Start Oct 16, 2024 · Primary completion Feb 5, 2028
Drug: RESP302; RESP303 · For: Non-Cystic Fibrosis Bronchiectasis
Sites: Kyiv, Ukraine
- A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPDPivotal-lookingActive, not recruiting
Generate BiomedicinesIndustry
NCT07116889 · 156 participants (planned) · Start Dec 12, 2023 · Primary completion May 2027
Drug: GB-0895 (SC); GB-0895 (SC) and 2 more · For: Asthma; COPD (Chronic Obstructive Pulmonary Disease)
Sites: DeLand, Florida; Miami, Florida; Orlando, Florida · 13 sites in all
- Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).Active, not recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.Industry
NCT06175351 · 80 participants (planned) · Start Jul 6, 2023 · Primary completion Sep 30, 2025
Drug: 9MW1911; Placebo · For: Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Sites: Baotou, China; Beijing, China; Changsha, China · 22 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.